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Autologous chondrocyte implantation (ACI), first reported 
in 1994,1 is a cell therapy option for the treatment of focal 
cartilage defects in articular joints, particularly the knee.2 
Although mid- to long-term durability has been demon-
strated with this technique,3-7 current recommendations 
from the National Institute for Health and Care Excellence8 
in the United Kingdom state that patients should be fully 
informed of the uncertainties about the long-term effective-
ness of ACI. Since not all patients benefit from ACI, recog-
nizing and understanding why the treatment was ultimately 
unsuccessful in these patients could influence who is 
selected for the procedure in the future. This would prevent 
subjecting these patients to an unnecessary treatment and 
hopefully help the search for a better treatment for this 
group. Treatment failure after ACI, however, has been 
inconsistently defined in studies,9 with various endpoints 
being used to define it. Loss of benefit in terms of clinical 
improvement, surgical re-intervention, or revision surgery 
are often used to evaluate risk factors for failure of joint 
reconstruction therapies.10-12 Total joint replacement has 
been suggested as a primary outcome for randomized clini-
cal trials of disease modifying osteoarthritis drugs because 
it represents failure of the “organ,”13-15 although this can be 
viewed as heavily influenced by the treating surgeon. Even 
recognizing that joint replacements can last several decades, 
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Abstract
Objective. The study had 2 objectives: first, to evaluate the success of autologous chondrocyte implantation (ACI) in 
terms of incidence of surgical re-intervention, including arthroplasty, and investigate predictors of successful treatment 
outcome. The second objective was to derive a tool predicting a patient’s arthroplasty risk following ACI. Design. In this 
Level II, prognostic study, 170 ACI-treated patients (110 males [aged 36.8 ± 9.4 years]; 60 females [aged 38.1 ± 10.2 
years]) completed a questionnaire about further surgery on their knee treated with ACI 10.9 ± 3.5 years previously. 
Factors commonly assessed preoperatively (age, gender, defect location and number, previous surgery at this site, and the 
preoperative Lysholm score) were used as independent factors in regression analyses. Results. At final follow-up (maximum 
of 19 years post-ACI), 40 patients (23.5%) had undergone surgical re-intervention following ACI. Twenty-six patients 
(15.3%) underwent arthroplasty, more commonly females (25%) than males (10%; P = 0.001). Cox regression analyses 
identified 4 factors associated with re-intervention: age at ACI, multiple operations before ACI, patellar defects, and lower 
pretreatment Lysholm scores (Nagelkerke’s R2 = 0.20). Six predictive items associated with risk of arthroplasty following 
ACI (Nagelkerke’s R2 = 0.34) were used to develop the Oswestry Risk of Knee Arthroplasty index with internal cross-
validation. Conclusion. In a single-center study, we have identified 6 factors (age, gender, location and number of defects, 
number of previous operations, and Lysholm score before ACI) that appear to influence the likelihood of ACI patients 
progressing to arthroplasty. We have used this information to propose a formula or “tool” that could aid treatment 
decisions and improve patient selection for ACI.
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patients having arthroplasty below the age of 50 are likely 
to outlast their implant and may need revision.16 This is a 
more complicated procedure, with the revision prosthesis 
often less effective, and has cost-benefit implications, both 
for the patient and health care provider.
We therefore investigated the clinical outcome in a large 
cohort of patients treated with ACI, identifying factors asso-
ciated with arthroplasty. Our overall aim was to develop an 
internally validated scoring system that could be used to aid 
the treatment decision-making process to better match the 
most appropriate treatment to each individual patient. In 
this study, we have determined the incidence of surgical re-
intervention after ACI treatment in our center, investigated 
which factors were associated with a return of the func-
tional outcome to its baseline value, or the requirement for 
further surgery after the treatment and, from this, developed 
a predictive tool to aid clinical decision making when con-
sidering ACI surgery.
Materials and Methods
Study participants consisted of a cohort of consecutive 
patients treated in our center with ACI (between 1996 and 
2010) for cartilage defects of the knee joint. Ethical approval 
for this retrospective study was obtained from the South 
Staffordshire Local Research Ethics Committee (Reference 
09/H1203/90), and patients, who had given their informed 
consent to the research study, were approached at least 12 
months after receiving an ACI and asked to complete a 
postal questionnaire. Follow-up time was calculated from 
the date of cell implantation in ACI to the date of question-
naire return. Clinical scores and details including indica-
tions for further surgery and arthroplasty were verified 
using hospital patient records. Patients treated with ACI for 
the presence of one or more grades II to IV chondral or 
osteochondral defects (Outerbridge classification17 or 
International Cartilage Repair Society score18) in their 
affected knee were identified using hospital records. 
Baseline measurements, features of defects, and co-inciden-
tal treatments were collected retrospectively using patient 
medical files. The ACI procedure was performed in 2 stages 
as previously described.1,6 Briefly, chondrocytes were iso-
lated from a small portion of full thickness cartilage har-
vested at arthroscopy (stage 1), and their numbers expanded 
in monolayer culture.19 An arthrotomy was performed 3 
weeks later (stage 2), during which the defect edges were 
cut back to healthy cartilage. Defect details were recorded 
on a knee diagram20 before the defect(s) were covered by 
periosteum (from the proximal medial tibia) or collagen 
membrane (Chondro-Gide; Pharma AG, Wolhusen, 
Switzerland). A suspension of the cultured chondrocytes in 
autologous serum was injected beneath the patch.
Immediately after ACI surgery, patients were provided 
with a rehabilitation protocol tailored to the site of the 
treated defect, outlining the appropriate level of motion and 
weight-bearing exercise to follow.21 The Lysholm score, a 
recommended patient-reported outcome measure for the 
knee,22-24 was used to assess improvement in clinical out-
come. One year following ACI, an arthroscopic procedure 
was offered to all patients as part of routine clinical follow-
up, during which hypertrophic cartilage growth, if present 
in the treated area, was debrided. This arthroscopy was not 
recorded as a re-intervention.
Failure of ACI was investigated based on 3 definitions: 
(1) the occurrence of knee arthroplasty, (2) the occurrence 
of any further surgery other than the routine follow-up 
arthroscopy at 1 year, and (3) the return of the functional 
outcome (Lysholm score) to its baseline value or below 
once past the 1-year post-ACI point.
Normally distributed continuous data (checked using 
Q-Q plots) were expressed in terms of mean ± standard 
deviation (SD), or otherwise expressed as median and inter-
quartile range (IQR). Associations between categorical 
variables were investigated using the chi-squared test. 
Preoperative and annual postoperative scores were com-
pared using a Wilcoxon signed-rank test for paired samples 
(e.g., baseline vs. 1-year scores) and a Mann-Whitney U 
test for independent samples (e.g., female vs. male patients). 
A Kaplan-Meier survival analysis was used to determine 
the cumulative risk of failure (arthroplasty, further surgery, 
or return to baseline Lysholm score) over time; cases that 
did not fail were censored at the end of their observation 
period. Differences between genders were tested using the 
log-rank test. Continuous and categorical predictors of the 
risk of return of functional outcome to baseline value, re-
intervention, or arthroplasty during the follow-up time were 
assessed using Cox proportional hazard models. The quality 
of the various predictors and predictive models was assessed 
using a generalization of the coefficient of determination 
(Nagelkerke’s R2).25,26 This coefficient captures aspects of 
calibration (the agreement between predicted and observed 
outcome) and discrimination (how well the score distin-
guishes between cases who do and do not fail),27 both of 
which are important in prognostic risk scores.28
The proportional hazard assumption was validated for 
each predictor identified by univariable Cox regression 
(with P < 0.15); the best-performing individual items were 
included into a multivariable Cox proportional hazard 
model. Model parameters were further optimized with a 
penalized regression method that used a shrinkage proce-
dure based on leave-one-out cross-validation.29 The cross-
validation step served as an internal validation of the 
prognostic model by repeatedly splitting the sample in a 
derivation sample, used to produce the model, and a valida-
tion sample, used to test the model. The shrinkage proce-
dure automatically prevented “overfitting” by reducing 
(shrinking) the coefficient value for predictors in the origi-
nal model that failed to predict the correct outcome in the 
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validation step.26 The result was an internally validated 
prognostic model.26
Statistical analyses were performed using SPSS version 
19.0 (SPSS Science Inc., Chicago, IL) and R version 2.13.0 
(R Foundation for Statistical Computing) with the 
“survival” and “penalized” packages. A 2-tailed P value of 
<0.05 was assumed to denote statistical significance; a list-
wise deletion approach was performed to handle missing 
data.
Results
A study questionnaire was sent to 202 knee patients treated 
with ACI in our center; 170 completed and returned it, cor-
responding to a response rate of 84%. The study cohort con-
sisted of 110 men and 60 women, with a mean age at ACI 
treatment of 36.8 ± 9.4 and 38.1 ± 10.2 years, respectively 
(P = 0.42); 6 surgeons had carried out the ACI procedures, 
with 83% being performed by one surgeon alone. The mean 
follow-up time for these patients was 10.9 ± 3.5 years post-
ACI (range = 4.6-18.6; Table 1). Twelve patients had no 
previous surgery of the knee before ACI, while 73 had one 
and 77 had multiple surgical procedures (up to a maximum 
of 11) on their knee prior to their ACI; details of previous 
surgery were unavailable for 8 patients.
Changes in the clinical outcome (Lysholm score) of the 
total patient population are shown in Figure 1. The median 
Lysholm score improved for the whole patient group from 
baseline to 1 year posttreatment (Wilcoxon signed- 
rank-test, P < 0.001) and improvement was sustained for a 
further 10 years post-ACI (Fig. 1); 72% (103/142) of 
patients were improved, 18% (25/142) had lower scores, 
and 10% (14/142) showed no improvement. Lysholm scores 
were significantly higher in males (75.0 [IQR = 50.0-83.3] 
Table 1. Patient Demographics Subdivided Into Patients With and Without Revision Surgery Post-ACI Treatment.
Patient Characteristics Total Patients (N = 170)
Patients Receiving Further Surgery
Yes (n = 40) No (n = 130)
Male–female 110:60 21:19 89:41
Age at ACI (years), mean ± SD [range] 37.3 ± 9.7 [15.1-65.8] 40.3 ± 10.4 [18.7-65.6] 36.3 ± 9.3 [15.1-65.8]
Follow-up time (years), mean ± SD [range] 10.9 ± 3.5 [4.6-18.6] 11.9 ± 2.9 [5.8-16.7] 10.6 ± 3.6 [4.6-18.6]
Age at follow-up (years), mean ± SD [range] 48.1 ± 10.2 [23.0-77.0] 52.1 ± 10.4 [33.0-77.0] 46.9 ± 9.8 [23.0-70.9]
Patients with single defects 124 26 98
Size of single defect (cm2), median [IQR] 4.0 [2.4-6.0] 4.2 [2.3-6.8] 3.7 [2.5-5.5]
Anatomical location of single defect
 Medial femoral condyle 74 14 60
 Lateral femoral condyle 28 6 22
 Patella 10 4 6
 Trochlea 8 2 6
 Lateral tibial plateau 3 1 2
 Medial tibial plateau 1 1 0
Patients with multiple defects 46 14 32
Previous operations [yes–no] (n) 151:12 (163) 37:2 (39) 114:10 (124)
Patients with co-incidental surgery [yes:no] 100:70 25:15 75:55
Normally distributed data summarized by mean ± standard deviation [range], and non-normally distributed data summarized by median (interquartile 
range [IQR]). ACI = autologous chondrocyte implantation.
Figure 1. Boxplot with whiskers of the preoperative (Pre) and 
annual Lysholm scores of all patients up to 10 years after ACI 
treatment. For those patients who underwent arthroplasty, no 
further Lysholm scores were recorded after this procedure. 
The central box spans the first quartile to the third quartile (the 
interquartile range), the segment inside shows the median, and 
the “whiskers” above and below the box show the locations 
of the minimum and maximum. Patient numbers for each time 
point are in parentheses.
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than females (56.3 [IQR = 41.7-79.2]; Mann-Whitney U 
test, P = 0.01) 1 year post-ACI, although the pre-operative 
scores were not significantly different (male [54.2; IQR = 
37.5-66.7] vs. female [43.8; IQR = 37.5-54.2], Mann-
Whitney U test, P = 0.062).
In all, 40 (23.5%) patients had undergone a further surgi-
cal procedure in the same knee compartment previously 
treated with ACI (Table 2). At 5 years, the cumulative risk 
of a further operation was 16%, increasing to 24% at 10 
years. When using the return of functional outcome 
(Lysholm score) to its baseline value or below as an indica-
tion of failure, 43% of patients had returned to baseline at 5 
years, 50% of patients at 8 years, and 61% of patients at 10 
years following ACI.
Twenty-six patients (15%) underwent knee arthroplasty 
4.4 ± 2.6 (range = 0.4-11.4) years after ACI. Lysholm scores 
for this patient group are shown in Figure 2; they recorded 
significantly lower pre-ACI Lysholm scores than those 
patients who did not have arthroplasty (41.7 [IQR = 25.0-
54.2] vs. 54.2 [IQR = 37.5-66.7], P < 0.005). While both 
groups demonstrated improvement in knee function at 1 
year post-ACI, this was greater and significant for those 
who did not progress to arthroplasty (Lysholm score 
increasing to 75.0 points [IQR = 50.0-83.3; P < 0.001; Fig. 
2A), compared to the lesser and not-significant increase 
seen for those who went on to have an arthroplasty (12 
month Lysholm of 45.8 [IQR = 35.4-59.4; P = 0.181; Fig. 
2B). The cumulative probability of remaining free from 
arthroplasty at 5 years was 90% (95% in male and 76% in 
female patients) and at 10 years was 84% (92% in males 
and 71% in females), corresponding to a significant differ-
ence in hazard rates between males and females (P < 0.001, 
log-rank test; Figure 3).
Significant individual categorical and continuous fac-
tors, identified using univariate Cox regression analyses, 
which influenced the likelihood of further surgery, were age 
at ACI, previous operations (none or single = 0, multiple = 
1), and preoperative Lysholm score (Table 3). Factors 
increasing the risk that clinical function would return to that 
recorded at baseline were having undergone a previous 
operation and a higher baseline Lysholm score (Table 4), 
while those influencing the likelihood of arthroplasty after 
ACI were age at ACI, gender (male = 0, female = 1), defect 
number, defects (single = 0, multiple = 1), patellar defect 
(no = 0, yes = 1), previous operations (none or single = 0, 
multiple = 1), and preoperative Lysholm score (Table 5). 
Multivariable analyses were then used to determine which 
combined predictors were associated with further surgery 
and arthroplasty after ACI. Age, patellar defects, multiple 
operations before ACI, and preoperative Lysholm score 
were, in combination, significantly associated with an 
increased risk of further surgery in the final multivariable 
model (Nagelkerke’s R2 = 0.20; Table 6). Likewise, more 
defects, having had multiple previous operations, undergo-
ing any parallel intervention, and a higher baseline Lysholm 
score were significantly associated with an increased risk 
Table 2. Types of Further Surgeries Performed during the 
Follow-Up Period in 40 Patients.
Surgery No. of Patients
Realignment 5
Autologous chondrocyte implantation 4
Chondroplasty 1
Mosaicplasty 2
Arthroplasty (unicompartmental or total) 26
Figure 2. Boxplot with whiskers of the preoperative (Pre) 
and annual Lysholm scores following autologous chondrocyte 
implantation treatment in patients who did not progress to 
arthroplasty (A) and those who did (B). No further Lysholm 
scores were recorded after patients had undergone arthroplasty. 
The central box spans the first quartile to the third quartile (the 
interquartile range), the segment inside shows the median, and 
the “whiskers” above and below the box show the locations 
of the minimum and maximum. Patient numbers for each time 
point are in parentheses.
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that clinical function would return to baseline levels 
(Nagelkerke’s R2 = 0.18; Table 7). Finally, age, female 
gender, patellar defects, defect number, multiple operations 
before ACI, and preoperative Lysholm score were signifi-
cantly associated with an increased risk of arthroplasty in 
the final multivariable model (Nagelkerke’s R2 = 0.34; 
Table 8).
This combination of 6 parameters (Table 8) represented 
the best-fit reduced model for predicting survival of ACI 
repair (with arthroplasty as the endpoint) and was used to 
construct an index of risk of arthroplasty post-ACI treat-
ment (the Oswestry Risk of Knee Arthroplasty index 
[ORKA-1 index]). First, the coefficients (in Table 8) were 
shrunk to minimize overfitting.29 Based on the adjusted 
coefficients of the optimized Cox model (Table 9), the “risk 
index” (RI) was constructed (RI = 0.054 × A + 0.9 × F + 0.9 
× NoD + 1.3 × P + MPO − 0.028 × PoL; where A = age, 
F = female, NoD = number of defects, P = patellar defect, 
MPO = multiple previous operations, PoL = pre-operative 
Lysholm score). An individual risk index was calculated 
(rounded to the nearest integer) for each patient in the study. 
Values for the whole group ranged from −1 to 8; patients 
with consecutive risk indices were grouped together when 
no statistically significant difference between them was 
found (Table 10).
To use the ORKA-1 index a patient’s risk index would 
first be calculated using this formula to find the patient’s 
designated risk group (groups 1-5). The chance of that 
patient requiring an arthroplasty in a period of 15 years after 
ACI procedure can then be estimated using Figure 4. For 
example, a patient in risk group 1 has approximately 1% 
chance of needing arthroplasty at 10 years after ACI, 
whereas a patient in risk group 3 has approximately a 70% 
chance.
Collagen membrane was used to cover the defects in 71 
patients (42%) and a periosteal patch used for 97 patients 
(57%). One patient with multiple defects received both 
periosteum and collagen membrane; patch details for one 
patient were unavailable. One year post-ACI, 74% (n = 
125) underwent a knee arthroscopy; of these, 80 (64%) had 
received periosteum, 44 (35%) a collagen membrane, and 1 
(1%) patient had received both patch types. Hypertrophic 
tissue was trimmed in 55 (44%) patients who had an arthros-
copy, 38/80 (48%) of patients with periosteum, and 17/40 
(43%) of patients with a collagen membrane (difference not 
significant, chi-squared test, P = 0.57).
Discussion
ACI has been used clinically for over 20 years to treat focal 
cartilage defects in articular joints, and it is clear that not all 
patients benefit. Identifying and understanding why ACI is 
not always successful could aid selecting the appropriate 
patient for this treatment in the future, improving outcomes 
and delaying or obviating the need for arthroplasty.
In our study of 170 patients (followed for up to 19 years), 
40 (23.5%) patients had further surgery at a mean of 11 
years post-ACI. This number did not include follow-up 
arthroscopies as in our center we have a long history of 
undertaking these as part of routine assessment and to pro-
vide prognostic advice,30 although now they are only under-
taken as part of a clinical trial. Although slightly higher than 
the percentage of patients reporting surgical re-intervention 
after ACI in some studies,31-34 we followed our patients for 
longer than most. A large study of >300 patients, comparing 
3 different ACI techniques over 4.5 years, reported that 
16.8% of patients needed re-intervention,34 but did not 
specify the nature of surgery. The same group went on to 
report further that in a group of 413 patients, 21.3% had 
undergone re-intervention within 5 years following ACI.35 
Other studies have included surgical re-intervention within 
their broad definition of “treatment failure.”4,6 One study 
reported an overall failure rate of 16% (at a mean of 7.4 
years post-ACI), ranging from 11% in patients with isolated 
condylar lesions to 24% with patellar lesions.6 Another 
large study evaluating the functional outcomes in >800 
patients treated with ACI/MACI reported an overall failure 
of 22% at 5 years and 49% beyond 10 years.4 The latter 
study included “return to baseline” in its definition of fail-
ure. Our finding that at 8 years 50% of patients and at 10 
years 61% of patients recorded that their clinical function 
had returned to baseline levels points to a similar result. 
When comparing these 2 studies, it is important to keep in 
mind that our patients return a score annually, which 
Figure 3. Kaplan-Meier survival analysis for all 170 patients 
receiving autologous chondrocyte implantation stratified by 
gender. Treatment failure, as defined by arthroplasty, was 
recorded in 26 patients (| and × show final follow-up points for 
individual patients [i.e., “censored” data], for males and females, 
respectively).
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increases the likelihood that a return of the Lysholm score 
to its baseline level is detected. It is also important to realize 
that due to ageing the natural trend of functional scores is 
downwards, something both studies did not account for 
when regarding “return to baseline” as a failure. A better 
insight in this natural trend is needed for a more realistic 
implementation of “return to baseline” in future studies.
A study of 40 patients treated with ACI (for single con-
dylar defects) reported reoperation rates of 5% at 2 years 
and 22.5% at 5 years, with 2.5% undergoing arthro-
plasty.32,33 In a longer-term durability study (over 10 years), 
4/72 patients (6%) had arthroplasty at 5-year follow-up and 
6/72 patients (8%) at 10 years.36 The incidence of arthro-
plasty in our study (10% at 5 years and 14% at 10 years) 
was higher than that reported in these other studies, but set 
against the large proportion of patients with multiple defects 
and patellar defects, both predicted to increase the risk of 
arthroplasty, this is perhaps not surprising.
Surgical re-intervention (or revision surgery) is often 
used as failure-endpoint to evaluate various therapies.10-12 
However, not all complications following ACI requiring re-
intervention should necessarily be perceived as indicating 
treatment failure. Some techniques such as debridement of 
a hypertrophic transplant have improved function and 
reduced pain.12 Higher age at ACI was identified as a risk 
factor for re-intervention and arthroplasty in our study, but 
not for a return of clinical function to that recorded at base-
line. Its role in predicting arthroplasty is not surprising 
since osteoarthritis is an age-associated disease.37 Most sur-
geons will not advise arthroplasty for the younger patient 
due to the finite lifespan of the prosthesis and subsequent 
complications. Patients having arthroplasty before age 50 
are likely to outlast their implant and require revision sur-
gery.16 Therefore, if ACI can delay having arthroplasty 
before that age it should be considered a successful proce-
dure, even if the joint eventually does require a prosthetic 
replacement.
Patients usually present in our clinic with complex 
pathologies since we are based in a secondary/tertiary refer-
ral center. An example is cartilage lesions of the patello-
femoral joint; many authors agree that these defects are the 
most difficult to treat.1,4,38 Concomitant surgeries to correct 
knee deformities with ligament instabilities or skeletal 
malalignment are now commonly performed with ACI 
(e.g., in 41% of our patients; Table 1). Increased success 
rates and benefits of combining treatments, such as realign-
ment procedures with cell therapy techniques, have been 
reported,6,39-41 demonstrating the importance of treating 
Table 3. Univariable Analysis of Influence from Categorical and Continuous Variables on the Survival of ACI Using Any Further 
Surgical Treatment as the Endpoint.
Variable P Value Hazard Ratio (95% CI) Nagelkerke’s R2
Age at ACI 0.013* 1.04 (1.01-1.08) 0.038
Gender (male = 0, female = 1) 0.057 1.83 (0.98-3.40 0.023
Defect number 0.058 1.61 (0.98-2.10) 0.021
Defects (single = 0, multiple = 1) 0.185 1.55 (0.81-2.98) 0.011
Maximum defect grade 0.717 1.11 (0.63-1.97) 0.001
Patch type (collagen = 0, periosteum = 1) 0.442 1.29 (0.67-2.48) 0.004
MFC defect (no = 0, yes = 1) 0.560 0.83 (0.45-1.55) 0.002
LFC defect (no = 0, yes = 1) 0.773 0.90 (0.43-1.88) 0.0006
Patellar defect (no = 0, yes = 1) 0.011* 2.55 (1.24-5.23) 0.035
Trochlear defect (no = 0, yes = 1) 0.573 0.78 (0.33-1.86) 0.002
MTP defect (no = 0, yes = 1) 0.340 1.65 (0.59-4.65) 0.005
LTP defect (no = 0, yes = 1) 0.411 1.64 (0.51-5.32) 0.004
Previous operations (no = 0, yes = 1) 0.524 1.59 (0.38-6.59) 0.003
Previous operations (none or single = 0, multiple = 1) 0.027* 2.10(1.09-4.03) 0.034
Previous microfracture (no = 0, yes = 1) 0.852 0.93 (0.43-2.02) 0.0002
Previous cartilage regenerationa (no = 0, yes = 1) 0.337 1.39 (0.71-2.70) 0.006
Parallel operation (no = 0, yes = 1) 0.742 0.90 (0.47-1.70) 0.0007
Parallel osteotomy (no = 0, yes = 1) 0.180 3.42 (1.34-8.74) 0.003
Parallel patella realignment (no = 0, yes = 1) 0.686 0.66 (0.09-4.85) 0.001
Parallel meniscal surgery (no = 0, yes = 1) 0.796 0.87 (0.31-2.45) 0.0005
Preoperative Lysholm score 0.001* 0.97 (0.95-0.99) 0.078
Calculation of P values, hazard ratios, and Nagelkerke’s R2 for each separate term determined from a univariable Cox model with that term. ACI = 
autologous chondrocyte implantation; CI = confidence interval; MFC = medial femoral condyle; LFC = lateral femoral condyle; MTP = medial tibial 
plateau; LTP = lateral tibial plateau.
aCartilage regeneration techniques included ACI, mosaicplasty, microfracture.
*Factor significantly influences risk of further surgery (P < 0.05).
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coexisting abnormalities if indicated.42 However, treatment 
of cartilage defects prior to ACI appears to influence out-
come adversely regardless of the failure definition. At least 
3 other studies report an association between increased fail-
ure risk and previous treatment,35,43 in particular marrow 
stimulation techniques.12 In our own study, patients under-
going multiple operations before ACI were at higher risk of 
arthroplasty.
In our study, patients requiring arthroplasty post-ACI 
were more likely to be female. A trial of ChondroCelect ver-
sus microfracture, similarly found higher failure rates for 
women in both treatment arms.44 Female gender has also 
been associated with a greater revision rate after ACI in 
another study.35 Hormonal influences on chondrogenic dif-
ferentiation, or differences in knee joint laxity, muscle 
strength, cartilage thickness, defect locations, and work-
related or other activities of daily living between the sexes 
may contribute to this difference in failure risk after ACI.45-49 
Our study also suggests that this higher rate of arthroplasty 
in females was not related to clinical function returning to 
baseline levels, because gender did not affect this reduction 
in Lysholm score. More subtle differences between the gen-
ders, such as in being offered the opportunity of a knee 
replacement or in accepting knee replacement, may thus also 
play a role. It is perhaps not surprising that gender is found 
to influence ACI outcome as differences between males and 
females have been noted for many years in the prevalence, 
incidence, and severity of joint disorders, including 
osteoarthritis.31,50
Various prognostic scoring systems are used in medicine, 
for example, predicting the incidence of knee osteoarthri-
tis,51,52 estimating life expectancy in cancer patients,53-56 and 
assessing stroke risk,56,57 but to our knowledge no other pre-
dictive tool currently estimates time to requiring arthroplasty 
after ACI. We have developed the ORKA-1 index to esti-
mate the long-term hazard of arthroplasty after ACI to be 
used before ACI treatment. We found that the preoperative 
Lysholm score was an important risk factor for the need for 
further surgery and arthroplasty after ACI. Improvement in 
Lysholm score generally occurs within the first 2 years after 
ACI,33,58 following which the Lysholm score remains con-
stant.58 Improvement in knee function can be maintained for 
over 10 years after treatment.6 We found that >70% of 
patients showed an improvement in clinical outcome at 1 
year, supporting previous findings.58 The group that went on 
to have arthroplasty were quite different, with no significant 
increase in 1-year Lysholm score, which then decreased rap-
idly with time post-ACI. We have included many parameters 
Table 4. Univariable Analysis of Influence from Categorical and Continuous Variables on the Survival of ACI Using the Return of the 
Functional Outcome (Lysholm score) to Its Baseline Value or Below as the Endpoint.
Variable P Value Hazard Ratio (95% CI) Nagelkerke’s R2
Age at ACI 0.38 1.01 (0.99-1.03) 0.005
Gender (male = 0, female = 1) 0.98 1.01 (0.68-1.50 0.000
Defect number 0.089 1.33 (0.96-1.85) 0.016
Defects (single = 0, multiple = 1) 0.21 1.31 (0.86-1.99) 0.009
Maximum defect grade 0.75 0.94 (0.64-1.37) 0.001
Patch type (collagen = 0, periosteum = 1) 0.57 0.89 (0.59-1.34) 0.002
MFC defect (no = 0, yes = 1) 0.72 0.93 (0.63-1.37) 0.001
LFC defect (no = 0, yes = 1) 0.70 0.91 (0.58-1.46) 0.001
Patellar defect (no = 0, yes = 1) 0.055 1.65 (0.99-2.76) 0.019
Trochlear defect (no = 0, yes = 1) 0.41 0.81 (0.49-1.34) 0.004
MTP defect (no = 0, yes = 1) 0.39 1.38 (0.67-2.85) 0.004
LTP defect (no = 0, yes = 1) 0.080 1.99 (0.92-4.31) 0.015
Previous operations (no = 0, yes = 1) 0.028* 2.77 (1.12-6.88) 0.039
Previous operations (none or single =0, multiple = 1) 0.018* 1.46 (1.07-2.00) 0.036
Previous microfracture (no = 0, yes = 1) 0.33 0.77 (0.46-1.29) 0.006
Previous cartilage regenerationa (no = 0, yes = 1) 0.38 1.00 (0.999-1.001) 0.004
Parallel operation (no = 0, yes = 1) 0.11 1.37 (0.93-2.02) 0.015
Parallel osteotomy (no = 0, yes = 1) 0.64 1.22 (0.53-2.80) 0.001
Parallel patella realignment (no = 0, yes = 1) 0.46 1.41 (0.57-3.48) 0.003
Parallel meniscal surgery (no = 0, yes = 1) 0.78 1.09 (0.61-1.95) 0.000
Preoperative Lysholm score 0.004* 1.02 (1.01-1.03) 0.054
Calculation of P values, hazard ratios, and Nagelkerke’s R2 for each separate term determined from a univariable Cox model with that term. ACI = 
autologous chondrocyte implantation; CI = confidence interval; MFC = medial femoral condyle; LFC = lateral femoral condyle; MTP = medial tibial 
plateau; LTP = lateral tibial plateau.
aCartilage regeneration techniques included ACI, mosaicplasty, microfracture.
*Factor significantly influences risk of further surgery (P < 0.05).
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that are regularly recorded in our center, but recognize that 
further parameters might also prove relevant. This index has 
been developed with first- and second-generation ACI, but it 
should be possible and relevant to be used as a predictive 
Table 6. Multivariable Analysis of the Influence of Preoperative Lysholm Score and Other Categorical and Continuous Parameters on 
the Survival of ACI Using Further Surgical Treatment as the Endpoint.
Variable Coefficient P Value Hazard Ratio (95% CI)
Full modela
 Age at ACI 0.04 0.099 1.04 (0.99-1.08)
 Gender (male = 0, female = 1) 0.55 0.121 1.74 (0.87-3.49)
 Defect number 0.45 0.128 1.57 (0.88-2.80)
 Patellar defect (no = 0, yes = 1) 1.10 0.011* 2.99 (1.29-6.94)
 Previous operations (none or single = 0, multiple = 1) 1.01 0.011* 2.75 (1.27-5.97)
 Pre-ACI Lysholm score −0.03 0.003* 0.97 (0.95-0.99)
Final modelb
 Age at ACI 0.05 0.025* 1.05 (1.01-1.09)
 Patellar defect (no = 0, yes = 1) 1.19 0.003* 3.29 (1.48-7.30)
 Previous operations (none or single = 0, multiple = 1) 1.01 0.008* 2.75 (1.30-5.79)
 Pre-ACI Lysholm score −0.03 0.002* 0.97 (0.95-0.99)
Calculation of P values and hazard ratios based on full Cox model (using all univariables with P < 0.15). ACI = autologous chondrocyte implantation; CI 
= confidence interval.
aNagelkerke’s R2 = 0.226 for the full model.
bNagelkerke’s R2 = 0.202 for the final model.
*Factor significantly influences risk of further surgery after ACI (P < 0.05).
Table 5. Univariable Analysis of Influence from Categorical and Continuous Variables on the Survival of ACI Using Arthroplasty as 
the Endpoint.
Variable P Value Hazard Ratio (95% CI) Nagelkerke’s R2
Age at ACI 0.000* 1.08 (1.04-1.12) 0.101
Gender (male = 0, female = 1) 0.009* 2.84 (1.30-6.19 0.051
Defect number 0.000* 2.85 (1.69-4.81) 0.092
Defects (single = 0, multiple = 1) 0.001* 3.64 (1.68-7.89) 0.076
Maximum defect grade 0.346 1.43 (0.68-3.03) 0.009
Patch type (collagen = 0, periosteum = 1) 0.451 0.74 (0.34-1.62) 0.004
MFC defect (no = 0, yes = 1) 0.570 0.80 (0.37-1.73) 0.002
LFC defect (no = 0, yes = 1) 0.734 1.16 (0.49-2.77) 0.0008
Patellar defect (no = 0, yes = 1) 0.001* 4.22 (1.87-9.53) 0.072
Trochlear defect (no = 0, yes = 1) 0.827 1.12 (0.42-2.96) 0.0003
MTP defect (no = 0, yes = 1) 0.293 1.91 (0.57-6.36) 0.007
LTP defect (no = 0, yes = 1) 0.539 1.57 (0.37-6.65) 0.0025
Previous operations (no = 0, yes = 1) 0.908 0.918 (0.22-3.89) 0.0001
Previous operations (none or single = 0, multiple = 1) 0.014* 2.99 (1. 25-7.16) 0.067
Previous microfracture (no = 0, yes = 1) 0.450 0.66 (0.23-1.93) 0.0049
Previous cartilage regenerationa (no = 0, yes = 1) 0.902 1.00 (0.99-1.00) 0.0001
Parallel operation (no = 0, yes = 1) 0.753 1.13 (0.52-2.47) 0.0007
Parallel osteotomy (no = 0, yes = 1) 0.190 4.13 (1.42-12.01) 0.0036
Parallel patella realignment (no = 0, yes = 1) 0.90 1.14 (0.15-8.49) 0.0001
Parallel meniscal surgery (no = 0, yes = 1) 0.94 1.05 (0.32-3.49) <0.0001
Preoperative Lysholm score 0.007* 0.97 (0.95-0.99) 0.059
Calculation of P values, hazard ratios, and Nagelkerke’s R2 for each separate term determined from a univariable Cox model with that term. ACI = 
autologous chondrocyte implantation; CI = confidence interval; MFC = medial femoral condyle; LFC = lateral femoral condyle; MTP = medial tibial 
plateau; LTP = lateral tibial plateau.
aCartilage regeneration techniques included ACI, mosaicplasty, microfracture.
*Factor significantly influences risk of arthroplasty (P < 0.05).
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factor for all biological or cell therapy treatment of chondral 
and osteochondral defects. There is certainly a need now for 
the ORKA-1 to be validated in a second population of ACI-
treated patients. The ORKA-1 index is now being used in the 
preoperative clinic in our center, which will likely provide 
this opportunity, but ideally it will also be tested and vali-
dated in other centers with different patient populations and 
surgeons. We also envisage that it will be modified and 
improved in the future, as well as simplifying its use. For 
example, it lends itself to being developed into a very easy to 
use “app” for use on smart phones and tablets in any location 
in the clinic.
As with all studies, the present one has some limitations. 
First, it is a single center study with the majority of patients 
being treated by one surgeon, so has the potential to be 
influenced by selection bias. On the other hand, it is based 
Table 8. Multivariable Analysis of the Influence of Preoperative Lysholm Score and Other Categorical and Continuous Parameters on 
the Survival of ACI Using Knee Arthroplasty as the Endpoint.
Variable Coefficient P Value Hazard Ratio (95% CI)
Full modela
 Age at ACI 0.07 0.007* 1.07 (1.02-1.12)
 Gender (male = 0, female = 1) 1.05 0.017* 2.85 (1.20-6.75)
 Defect number 1.57 0.020* 4.83 (1.28-18.24)
 Defects (single = 0, multiple = 1) −0.89 0.352 0.41 (0.06-2.67)
 Patellar defect (no = 0, yes = 1) 1.68 0.002* 5.38 (1.89-15.29)
 Previous operations (none or single = 0, multiple = 1) 1.23 0.020* 3.42 (1.22-9.64)
 Pre-ACI Lysholm score −0.03 0.017* 0.97 (0.94-0.99)
Final modelb
 Age at ACI 0.07 0.009* 1.07 (1.02-1.12)
 Gender (male = 0, female = 1) 1.00 0.021* 2.71 (1.164-6.31)
 Defect number 1.01 0.002* 2.73 (1.45-5.15)
 Patellar defect (no = 0, yes = 1) 1.66 0.002* 5.26 (1.87-14.79)
 Previous operations (none or single = 0, multiple = 1) 1.32 0.011* 3.75 (1.36-10.38)
 Pre-ACI Lysholm score −0.04 0.018* 0.966 (0.94-0.99)
Calculation of P values and hazard ratios based on full Cox model (using all univariables with P < 0.15). ACI = autologous chondrocyte implantation; CI 
= confidence interval.
aNagelkerke’s R2 = 0.345 for the full model.
bNagelkerke’s R2 = 0.339 for the final model.
*Factor significantly influences risk of arthroplasty (P < 0.05).
Table 7. Multivariable Analysis of the Influence of Preoperative Lysholm Score and Other Categorical and Continuous Parameters on 
the Survival of ACI Using the Return of the Functional Outcome (Lysholm Score) to Its Baseline Value or Below as the Endpoint.
Variable Coefficient P Value Hazard Ratio (95% CI)
Full modela
 Defect number 0.37 0.064 1.44 (0.98-2.12)
 Patellar defect (no = 0, yes = 1) 0.51 0.11 1.67 (0.89-3.11)
 LTP defect (no = 0, yes = 1) 0.24 0.60 1.27 (0.52-3.09)
 Previous operations (none or single = 0, multiple = 1) 0.62 <0.001* 1.85 (1.29-2.65)
 Parallel operation (no = 0, yes = 1) 0.33 0.18 1.39 (0.86-2.26)
 Pre-ACI Lysholm score 0.025 <0.001* 1.03 (1.02-1.04)
Final modelb
 Defect number 0.46 0.012* 1.58 (1.11-2.26)
 Previous operations (none or single = 0, multiple = 1) 0.57 <0.001* 1.77 (1.26-2.48)
 Parallel operation (no = 0, yes = 1) 0.44 0.049* 1.55 (1.00-2.40)
 Pre-ACI Lysholm score 0.024 <0.001* 1.03 (1.01-1.04)
Calculation of P values and hazard ratios based on full Cox model (based on all univariables with P < 0.15). ACI = autologous chondrocyte implantation; 
CI = confidence interval. LTP = lateral tibial plateau.
aNagelkerke’s R2 = 0.188 for the full model.
bNagelkerke’s R2 = 0.175 for the final model.
*Factor significantly influences risk of further surgery after ACI (P < 0.05).
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on a heterogeneous group of patients with cartilage defects 
representing a mixed group in terms of age, size of defect, 
anatomical location of defect, co-injuries, and previous sur-
gery, which will help generalization to new patient cohorts. 
Our broad study inclusion criteria compared with those of 
typical clinical trials (e.g., Knutsen et al.32), makes our 
study cohort perhaps more representative of patients with a 
more severe and complex disease. Not only have random-
ized clinical trials usually a more narrowly defined study 
population but they also have potentially high expecta-
tions.59 Our patient group is perhaps more representative of 
the general population with cartilage injuries or early osteo-
arthritis.60 Unfortunately, the data set is not 100% complete 
for all patients treated in our center with some values miss-
ing for 30 of the 170 patient group. While this is not perfect, 
and undoubtedly would have been much smaller if the study 
had been a proper clinical trial, the missing data only repre-
sent aspects of the patients and is probably missing com-
pletely at random. The total number of patients is quite high 
and covers a long time span compared to most other studies 
reported in the literature. A final limitation is that, although 
we have performed an internal validation of the ORKA 
index using a cross-validation and shrinking procedure to 
guard against overoptimism,26 our predictive model still 
requires external validation.
In conclusion, the incidence of further surgery post-ACI 
treatment within our study over an average of 11 years was 
23.5%. The incidence of joint failure (or the requirement for 
arthroplasty) was 15%, more commonly in females. Age, 
gender, defect number and location, previous surgery, and 
preoperative Lysholm score are important factors to con-
sider when deciding which patients would benefit most 
from ACI for cartilage defects in the knee. We propose that 
combining these predictors into the ORKA index to esti-
mate the likely time to arthroplasty will help both the patient 
and surgeon decide whether to proceed with ACI as an 
appropriate surgical option for the treatment of cartilage 
defects.
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Table 10. Risk Groups for Survival to Knee Arthroplasty.
Risk Index Value 
(Rounded)
No. of Patients 
in Study Risk Group
−1, 0, 1, 2 66 1




Patients within the same risk group have survival probabilities that could 
not be distinguished using a log-rank test. In our study, no patients with 
a score of 7 was present.
Figure 4. Survival of autologous chondrocyte implantation 
repair with knee arthroplasty as the endpoint for patients in this 
study belonging to the 5 identified risk groups (1-5).
Table 9. Factors and Their Multipliers in the Prognostic Model.
Factor Multiplier
Age (A) 0.054
Female (F; score 1 if female, otherwise 0) 0.9
No. of defects (NoD) 0.9
Patellar defect (P; score 1 if patellar defect, 
otherwise 0)
1.3
Multiple previous operations (MPO; score 
1 if MPO, otherwise 0)
1
Preoperative Lysholm score (PoL) −0.028
Multipliers based on penalized cross-validated Cox regression model.
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